This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety Study of Fentanyl Transdermal (Fentanest®)

This study has been withdrawn prior to enrollment.
Information provided by:
Cristália Produtos Químicos Farmacêuticos Ltda. Identifier:
First received: August 13, 2009
Last updated: July 15, 2015
Last verified: July 2015
Eligible patients who agree to participate will migrate from oral opioids to transdermal patches and be followed for four weeks. Oral morphine will be provided as pain rescue medication. The patients will inform the adverse events and rescue medication consumption. The number of Fentanest® patches will be adjusted every visit aiming to reduce the rescue medication consumption and adverse events to a minimum. The WHO-QOL- bref (quality of life questionary) will be filled before and after the use of Fentanest®. Patients showing benefit are eligible to a 3 weeks compassionate study.

Condition Intervention Phase
Pain Palliative Care Drug: Fentanyl Transdermal Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Cristália Produtos Químicos Farmacêuticos Ltda.:

Primary Outcome Measures:
  • Primary: formulation tolerability (assessed by adverse events incidence). Co primary: formulation analgesic efficacy (assessed by rescue medication demand). [ Time Frame: 4 weeks folow-up ]

Secondary Outcome Measures:
  • Establish the correspondence between the dose of oral opioids available in Brazil and number of patches required. Establish directions for secure and effective migration from oral opioids to this formulation. Quality of life improvement (WHO-QOL-bref). [ Time Frame: 3 months ]

Enrollment: 0
Study Start Date: November 2009
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fentanyl Transdermal Drug: Fentanyl Transdermal
Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female outpatients aged from 18 to 70 years with cancer chronic pain who received in the last 4 weeks at least 40 mg of oral morphine or equianalgesic dose of other opioids. If using adjuvant analgesics, these must be in stable doses in the last 4 weeks.

Exclusion Criteria:

  • Life expectancy bellow 4 months;
  • Karnofsky score < 60;
  • Hypersensitivity to opioids or patches;
  • Acute pain;
  • Non cancer pain;
  • Increased intracranial pressure;
  • Conditions that prevent the patient to understand the study directions and/or give his consent;
  • Neuromuscular disorders with increased risk of respiratory depression;
  • Impossibility to receive rescue oral morphine; active infections;
  • Fever;
  • Pregnancy and nursing;
  • Uncontrolled diabetes mellitus or arterial hypertension;
  • Need of anticoagulation;
  • Need to operate machines or vehicles;
  • Important skin disorders;
  • History of severe allergic reactions;
  • BMI ≥ 35;
  • Safety exams outrange;
  • Participation in another clinical trial within the last 2 months;
  • Investigator´s opinion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00959400

Hospital Universitario da Universidade Federal do Maranhao
Sao Luis, Maranhao, Brazil, 65020-070
Hospital das Clinicas da Faculdade de Medicina da Universidade Estadual Paulista "Julio de Mesquita Filho" - Campus de Botucatu - Unesp
Botucatu, Sao Paulo, Brazil, 18618-970
Instituto Nacional de Cancer - Hospital do Cancer I
Rio de Janeiro, Brazil, 20230-130
Hospital A. C. Camargo
Sao Paulo, Brazil, 01509-010
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP
Sao Paulo, Brazil, 05403-000
Sponsors and Collaborators
Cristália Produtos Químicos Farmacêuticos Ltda.
  More Information

Responsible Party: Eduardo Pagani, CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA Identifier: NCT00959400     History of Changes
Other Study ID Numbers: CRT059
Study First Received: August 13, 2009
Last Updated: July 15, 2015

Keywords provided by Cristália Produtos Químicos Farmacêuticos Ltda.:
Fentanyl Transdermal

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anesthetics processed this record on June 22, 2017